Stock A222110 PANGEN BIOTECH INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News PanGen Biotech Inc.

Equities

A222110

KR7222110009

End-of-day quote Korea S.E.
Other stock markets
 18:00:00 2024-05-27 EDT 		5-day change 1st Jan Change
5,570 KRW +4.31% Intraday chart for PanGen Biotech Inc. -0.54% -19.04%
03-27 PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI
03-18 PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd. CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PanGen Biotech Inc. announced that it has received KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.999986631 billion in funding from CrystalGenomics Invites Co., LTD., Huons Co., Ltd., Hwail Pharmaceutical Co.,Ltd.
CI
PanGen Biotech Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
PanGen Biotech Inc. announced that it has received KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
CI
PanGen Biotech Inc. announced that it expects to receive KRW 3.2 billion in funding from Eugene Investment & Securities Co.,Ltd., Samsung Securities Co., Ltd.
CI
CrystalGenomics, Inc. agreed to acquire 20.43% stake in PanGen Biotech Inc. from the group of shareholders for approximately KRW24 billion.
CI
PanGen Biotech Inc. announced that it has received KRW 9.99998571 billion in funding from Huons Co., Ltd. and another investor
CI
PanGen Biotech Inc. announced that it expects to receive KRW 9.99998571 billion in funding from Huons Co., Ltd., and another investor
CI
Huons Lab Forms Partnership with Pangen Biotech to Co-Develop Human Genetic Recombinant Hyaluronidase
CI
PanGen Biotech Inc.(KOSDAQ:A222110) dropped from S&P Global BMI Index
CI
CCM Duopharma Biotech Berhad completed the acquisition of 8.4% stake in PanGen Biotech Inc. from Chemical Company of Malaysia Berhad.
CI
CCM Duopharma Biotech Berhad entered into agreement to acquire PanGen Biotech Inc. from Chemical Company of Malaysia Berhad for KRW 16.4 billion.
CI
Chemical Companies In Talks To Sell Non Core Assets
CI
PanGen Biotech Inc. announced that it has received KRW 18 billion in funding
CI
PanGen Biotech Inc. announced that it expects to receive KRW 18 billion in funding
CI
PanGen Biotech Inc.(KOSDAQ:A222110) added to S&P Global BMI Index
CI
PanGen Biotech Inc. has completed an IPO in the amount of KRW 27.23 billion.
CI
PanGen Biotech Inc. has filed an IPO in the amount of KRW 18.75 billion.
CI
PanGen Biotech Inc. has withdrawn its IPO in the amount of KRW 35.40 billion.
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A222110 Stock
  4. News PanGen Biotech Inc.